Immunohistochemistry, Neutralization, Flow Cytometry, ELISA Capture, ELISA Development, ELISA Development (Capture), In vivo assay, Luminex Development

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG₁ Clone # 67604

View all G-CSF Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant mouse G-CSF
Val31-Ala208
Accession # P09920

Specificity

Detects mouse G-CSF in ELISAs and Western blots. In ELISAs, does not cross-react with recombinant human (rh) G‑CSF, rhCNTF, rmIL-6, rmLIF, or rmOSM.

Clonality

Monoclonal

Host

Rat

Isotype

IgG₁

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Mouse G-CSF Antibody

Cell Proliferation Induced by G-CSF and Neutralization by Mouse G-CSF Antibody.

Recombinant Mouse G-CSF (Catalog # 414-CS) stimulates proliferation in the NFS-60 mouse myeloid cells line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse G-CSF (125 pg/mL) is neutralized (green line) by increasing concentrations of Mouse G-CSF Monoclonal Antibody (Catalog # MAB414). The ND₅₀ is typically 0.01-0.03 µg/mL.

Detection of G-CSF by Immunohistochemistry

G-CSF, but neither IL-17 nor Bv8, was still essential to the intratumor recruitment of PMN-MDSCs and antitumor angiogenesis in the LLC tumor model(A) Confirmation that G-CSF, but not IL-17, was involved in anti-VEGF-mediated upregulation in LLC tumor lysate assessed by ELISA assay. (n = 6/group). (B) Neither anti-VEGF nor capecitabine affected Bv8 expression as assessed by ELISA. (n = 6/group). (C) Effects of anti-VEGF, anti-G-CSF, and their combination on LLC tumor angiogenesis. The PECAM-1-positive vascular surface area was identified by immunohistochemistry. Only the combination, but not either sole therapy, could reduce the tumor angiogenesis. (n = 6/group). (D) Effects of anti-VEGF, capecitabine, and their combination on LLC tumor angiogenesis. The PECAM-1-positive vascular surface area was identified by immunohistochemistry. Note that only the combination, but not either sole therapy, could reduce the tumor angiogenesis, similarly to the findings to shown in panel (C). Data are mean ± SEM. N.S.: not significant, *P < 0.01, and #P < 0.05. (n = 5–6/group). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29707135), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of G-CSF by Flow Cytometry

G-CSF neutralization decreases BM granulopoiesis, restores BM erythropoiesis, and suppresses splenic erythropoiesis in LPS-treated mice.(N) Representative flow cytometric plots of CD11b+Ly6G+ cells in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33234677), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of G-CSF by Flow Cytometry

G-CSF neutralization decreases BM granulopoiesis, restores BM erythropoiesis, and suppresses splenic erythropoiesis in LPS-treated mice.(D) Representative flow cytometric plots of CD71+Ter119+ cells in the BMs of control mice, LPS-treated mice, and LPS-treated mice with anti-G-CSF treatment. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33234677), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of G-CSF by Flow Cytometry

G-CSF neutralization decreases BM granulopoiesis, restores BM erythropoiesis, and suppresses splenic erythropoiesis in LPS-treated mice. (K) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the spleen of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33234677), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of G-CSF by Immunohistochemistry

G‐CSF and MIP‐2 in exosomes were the main protection effectors in testis radiation protection. A, On day 7 after neutralizing antibody administration and 4 Gy irradiation, mice testis was isolated and subjected to H&E staining. B, Clonal formation assay was used to determine GC‐1 cell viability after exosomes treatment and irradiation exposure with or without neutralizing antibody. Data were presented as mean ± SD (n = 3). *P < .05. **P < .01, ***P < .001 Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32135028), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of G-CSF by Flow Cytometry

G-CSF neutralization decreases BM granulopoiesis, restores BM erythropoiesis, and suppresses splenic erythropoiesis in LPS-treated mice. (F) Representative flow cytometric profiles of Ter119-APC and thiazole orange–stained cells from the BM of control mice, LPS-treated mice, and LPS-treated mice with anti–G-CSF treatment. (G) Flow cytometric quantification of reticulocytes (Ter119+ Thiazole orange+) in the BM of mice. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/33234677), licensed under a CC-BY license. Not internally tested by R&D Systems.

View 4 more images

Applications for Mouse G-CSF Antibody

Application

Recommended Usage

Western Blot

1 µg/mL
Sample: Recombinant Mouse G-CSF (Catalog # 414-CS)

Neutralization

Measured by its ability to neutralize G‑CSF-induced proliferation in the NFS‑60 mouse myeloid cells line. Shirafuji, N. et al. (1989) Exp. Hematol. 17:116. The Neutralization Dose (ND₅₀) is typically 0.01-0.03 µg/mL in the presence of 0.125 ng/mL Recombinant Mouse G‑CSF.

Mouse G-CSF Sandwich Immunoassay

ELISA Capture (Matched Antibody Pair)

Recommended Concentration: 2-8 µg/mL
Use in combination with these reagents:

Detection Reagent: Mouse G-CSF Biotinylated Antibody (Catalog # BAF414)
Standard: Recombinant Mouse G-CSF Protein (Catalog # 414-CS)

Please Note: Optimal dilutions of this antibody should be experimentally determined.

Reviewed Applications

Read 3 reviews rated 4 using MAB414 in the following applications:

ELISA (1 Review)
Immunocytochemistry/Immunofluorescence (1 Review)
Immunohistochemistry (1 Review)

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: G-CSF

G-CSF is a pleiotropic cytokine best known for its specific effects on the proliferation, differentiation, and activation of hematopoietic cells of the neutrophilic granulocyte lineage. It is produced mainly by monocytes and macrophages upon activation by endotoxin, TNF-alpha and IFN-gamma. Other cell types including fibroblasts, endothelial cells, astrocytes and bone marrow stromal cells can also secrete G-CSF after LPS, IL-1, or TNF-alpha activation. In addition, various carcinoma cell lines and myeloblastic leukemia cells can express G-CSF constitutively.

The murine G-CSF cDNA encodes a 208 amino acid (aa) residue precursor protein containing a 30 aa residue signal peptide that is proteolytically cleaved to generate the 178 aa residue mature protein. Human G-CSF is 73% identical at the amino acid level to murine G-CSF and the two proteins show species cross-reactivity.

In vitro, G-CSF stimulates growth, differentiation and functions of cells from the neutrophil lineage. It also has blast cell growth factor activity and can synergize with IL-3 to shorten the G_o period of early hematopoietic progenitors. Consistent with its in vitro functions, G-CSF has been found to play important roles in defense against infection, in inflammation and repair, and in the maintenance of steady state hematopoiesis. Recombinant human G-CSF has been approved for the amelioration of chemotherapy induced neutropenia as well as for severe chronic neutropenia following marrow transplant.

Long Name

Granulocyte Colony Stimulating Factor

Alternate Names

C17orf33, CSF3, CSF3OS, Filgrastim, GCSF, Lenograstim, Pluripoietin

Entrez Gene IDs

1440 (Human); 12985 (Mouse)

Gene Symbol

CSF3

UniProt

P09920

Additional G-CSF Products

Product Documents for Mouse G-CSF Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Mouse G-CSF Antibody

For research use only

Citations
Reviews